PP
ALDX icon

PDT Partners’s Aldeyra Therapeutics ALDX Stock Holding History

PDT Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,402
Closed -$169K – 706
2024
Q3 		$169K Buy
+31,402
New +$149K 0.02% 671
2022
Q2 		– Sell
-18,470
Closed -$82K – 940
2022
Q1 		$82K Buy
+18,470
New +$73.6K 0.01% 883

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

PDT Partners's ALDX Position: Q4 2024 in Review

PDT Partners sold out of Aldeyra Therapeutics (ALDX) in Q4 2024, closing a stake of 31,402 shares — an estimated $169K sold.

PDT Partners first reported a position in ALDX in Q1 2022 and held it in 2 quarters. The position peaked at $169K in Q3 2024. 118 funds tracked by Wall St. Rank hold ALDX as of Q4 2024.

  • PDT Partners reported no remaining Aldeyra Therapeutics position as of Q4 2024 after selling out during the quarter.
  • PDT Partners sold 31,402 Aldeyra Therapeutics shares in Q4 2024, an estimated $169K.
  • PDT Partners first reported a position in Aldeyra Therapeutics in Q1 2022 and held it in 2 quarters.
  • PDT Partners's Aldeyra Therapeutics position peaked at $169K in Q3 2024.
  • 118 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.